CrossRef Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses Ji Eun Jun, Da-Hee Oh, In-Kyung Jeong, Hyun Jin Ryu, You-Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Kwang Pyo Kim Frontiers in Endocrinology.2026;[Epub] CrossRef Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique Carlos A
How Much Does Ipamorelin + CJC-1295 DAC Cost
This level of detail supports medical necessity and prevents downcoding during audits
#Endocrinology #Obesity #GLP1 #Medicare #Diabetes To view or add a comment, sign in -1 Very interesting paper just published in JAMA by Ashwin Chetty and colleagues
Genetic predispositions do not predict exact medication response, but they may reveal whether you have favorable receptor pathways (suggesting lower-cost, lower-dose options may work well) or less favorable variants (suggesting dual-agent or higher-dose compounds may offer better clinical return on investment)
In the past decade, three major forms of neighbourhood co-governance have emerged: state-led co-creation, professional-led place-making, and enterprise-party co-development, which is led by the local state, societal actors, and market actors respectively
